The size of the MEA pyrogen testing market is predicted to be worth USD 128.3 million by 2028 from USD 74.82 million in 2023, growing at a CAGR of 11.39% during the forecast period.
The growing focus on personalized medicine, increased R&D in the pharmaceutical and biotechnology industries, increased awareness of food safety, as well as investments in research and development, technological advancements, and new drug launches, and rising incidence of infectious diseases and pandemics are majorly driving the Middle East and Africa pyrogen testing market expansion. Pyrogen contamination is common in pharmaceuticals and medical devices, and it is sometimes to blame for infecting patients with life-threatening illnesses.
The pyrogen testing technique is so important, and the MEA market for pyrogen testing continues to grow. As a result, increasing demand for pyrogen testing is expected over the forecast period. For instance, a rise in body temperature is a common immunological response seen in the development of many chronic and acute diseases. The rise in such disorders among the elderly has boosted the demand for pyrogen diagnostics. Furthermore, the rising prevalence of chronic diseases in this region has raised the demand for pyrogen testing, which, together with raising awareness, is likely to result in rapid development during the forecast period. In addition, endotoxin identification products can help with infectious illness management, especially in countries where healthcare infrastructure is lacking. This has resulted in a rise in pyrogen testing products, helping the Middle East Africa market grow.
Only large corporations can afford high capital expenditures as well as high R&D and manufacturing costs. However, the pyrogen testing market is likely to be restricted by a lack of healthcare facilities and a scarcity of modern pyrogen testing instruments throughout the forecast period. Furthermore, the market's growth is hampered by a high level of regulatory restrictions. The increased availability of many generics, tough competition, and growing popularity of sustainable chemistry are among the primary reasons that will hamper market expansion and are estimated to provide further challenges to the MEA pyrogen testing market.
Because of the increased awareness of pyrogen testing over the last few decades, per capita, healthcare spending has nearly doubled. Increasing healthcare spending will likely lead to increased demand for higher-quality pharmaceuticals and medical devices, which is expected to provide profitable growth opportunities for Middle East Africa pyrogen testing market players during the forecast period. Manufacturers also employ new product development and launch as a critical strategy for maintaining market dominance and increasing revenue share. Furthermore, technological developments and the launch of new medications aid market development.
This research report on the Middle East and Africa Pyrogen Testing Market has been segmented and sub-segmented into the following categories:
By Test Type:
South Africa is likewise working to establish itself as a worldwide biotech center, focusing on biosimilars, vaccine development, and stem cell therapies. Furthermore, the growing need for rehabilitative treatments for life-threatening diseases like cancer and diabetes underscores the need for medication research and development. Thus, the demand for pyrogen testing kits for effective quality testing and management. In addition, companies are implementing good manufacturing practices through biological testing at various stages of the production cycle, adding to the market's growth in MEA.
KEY MARKET PLAYERS:
Companies that are playing a notable role in the MEA pyrogen testing market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck Kgaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc., and WUXI Pharmatech (Cayman) Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org